Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01884051 · ClinicalTrials.gov registry record
Hormonal, Metabolic, and Signaling Interactions in PAH
A clinical trial of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- 1,899
- Enrollment target
- 1
- Study location
NCT01884051: Recruiting study of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension, sponsored by Vanderbilt University Medical Center.
NCT01884051 is a study of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 1,899 participants, above the 82-participant average among 3 other Idiopathic Pulmonary Arterial Hypertension trials with a reported enrollment target (2216% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01884051, a study of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- 1,899 participants
- Enrollment target
- 1
- Study location
Study Summary
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
Primary Outcome
The primary outcome measure is the ratio of 2-hydroxyestrogens to 16-hydroxyestrogens among patients compared to both controls and at risk but well subjects.
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,899 participants |
| Start Date | 2012-09 |
| Est. Completion | 2032-07 |
What NCT01884051 shows while recruiting
NCT01884051 is an observational study that tracks outcomes without assigning an intervention. Its 1,899 participants enrollment target places it among the larger protocols in the corpus, above the 82-participant average among 3 other Idiopathic Pulmonary Arterial Hypertension trials with a reported enrollment target (2216% higher).
The record links to 4 conditions, with Idiopathic Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT01884051 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT01884051 about?
NCT01884051 is a clinical study titled "Hormonal, Metabolic, and Signaling Interactions in PAH". Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
What is the current status of trial NCT01884051?
This trial is currently recruiting. The enrollment target is 1,899 participants. The study started on 2012-09. Estimated completion is 2032-07.
What conditions does trial NCT01884051 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH.
Who is sponsoring clinical trial NCT01884051?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01884051 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
RECRUITING
-
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia